(Q33706946)

28 July 2017

1 reference

title

Immune and gene therapy for melanoma, and the immunobiology of melanoma (English)

1 reference

28 July 2017

0 references

Smith KJ

1

1 reference

28 July 2017

Skelton H

series ordinal

2

1 reference

28 July 2017

language of work or name

1 reference

1 July 1999

1 reference

International Journal of Dermatology

28 July 2017

published in

1 reference

28 July 2017

volume

38

1 reference

28 July 2017

issue

7

1 reference

28 July 2017

page(s)

490-508

1 reference

28 July 2017

cites work

Cancer statistics, 1997.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Cancer incidence and mortality, 1973-1995: a report card for the U.S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Epidemiology of Malignant Melanoma: Intermittent or Total Accumulated Exposure to the Sun?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Chemoprevention of ultraviolet radiation-induced skin cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Audit of public education campaign to encourage earlier detection of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Adjuvant therapy for cutaneous malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Favorable prognostic factors in recurrent and metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Tumor antigens recognized by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Sequence and expression pattern of the human MAGE2 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Cancer vaccines based on the identification of genes encoding cancer regression antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

What's new in the treatment of cutaneous melanoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Immunological ignorance of silent antigens as an explanation of tumor evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Inactivation of the E-cadherin-mediated cell adhesion system in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Coordinate regulation of the human TAP1 and LMP2 genes from a shared bidirectional promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

cDNA cloning and interferon gamma down-regulation of proteasomal subunits X and Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Limiting dilution analysis of human T cells: a useful clinical tool

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guérin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

New approaches to treating advanced melanoma: adjuvant treatment of high-risk primary melanoma and boron neutron capture therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Interleukin-7 induces differential lymphokine-activated killer cell activity against human melanoma cells, keratinocytes, and endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

B cells inhibit induction of T cell-dependent tumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Normal human melanocytes that express a bFGF transgene still require exogenous bFGF for growth in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Regulation by interferon alpha of immunoglobulin isotype selection and lymphokine production in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Virus vector design in gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Administration of recombinant interferon gamma to cancer patients enhances monocyte secretion of hydrogen peroxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Surface antigens of melanoma and melanocytes. Specificity of induction of Ia antigens by human gamma-interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

21 January 2018

Non-viral gene therapy

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Gene therapy against cancer and HIV infection using the gene encoding herpes simplex virus thymidine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Gene vaccination: plasmid DNA is more than just a blueprint

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

DNA immunization targeting the skin: molecular control of adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Antibody-directed enzyme prodrug therapy for cancer: its theoretical basis and application

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

Regulation of KIR expression in human T cells: a safety mechanism that may impair protective T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-4362.1999.00746.X

10.1046/J.1365-4362.1999.00746.X

21 January 2018

Identifiers

DOI

1 reference

28 July 2017

1 reference